In Q1 FY2026 (ended March 31, 2026), Jade Biosciences reported no revenue and a net loss of $40.4 million, a 5.8% increase from the prior year. Operating loss was $43.4 million, up 85.8% year-over-year. Diluted EPS was -$0.57, improving from -$0.29. The company held $55.1 million in cash and $296.5 million in equity, with no long-term debt.
•No revenue generated; net loss of $40.4 million.
•Operating loss widened 85.8% to $43.4 million.
•Diluted EPS improved to -$0.57 from -$0.29.
•Cash of $55.1 million and equity of $296.5 million; no long-term debt.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Jade Biosciences is a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial.
It also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Jade Biosciences, Inc. is a biotechnology company focused on developing therapies for inflammation and immunology indications in patients living with autoimmune diseases. Its lead product candidate is JADE101, a monoclonal antibody designed to block the A PRoliferation Inducing Ligand (APRIL) protein, which is currently in a phase 1 clinical trial. The company also has two preclinical-stage candidates: JADE201 and JADE-003. These programs aim to address unmet medical needs in autoimmune conditions. Jade Biosciences is headquartered in Waltham, Massachusetts, and operates in the United States.
Where is Jade Biosciences (JBIO) listed and what currency does it trade in?
Jade Biosciences, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol JBIO. Its shares are traded in U.S. dollars (USD). The NasdaqCM is a U.S.-based stock exchange that typically lists smaller-cap companies, and Jade Biosciences qualifies as a biotechnology firm in the healthcare sector. Investors can buy and sell JBIO shares during regular trading hours on the NasdaqCM, with all transactions denominated in USD.
What sector and industry does Jade Biosciences (JBIO) belong to?
Jade Biosciences, Inc. operates in the Healthcare sector and is classified under the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies, specifically for inflammation and immunology indications related to autoimmune diseases. The company's pipeline includes monoclonal antibodies and other biologic drugs, which are typical of the biotechnology industry. This classification helps investors understand the regulatory and market environment in which Jade Biosciences operates, including the high-risk, high-reward nature of drug development.
Where is Jade Biosciences (JBIO) headquartered and what is its geographic focus?
Jade Biosciences, Inc. is based in Waltham, Massachusetts, United States. The company's operations and research activities are centered in the U.S., and it primarily serves the American market. Waltham is part of the Greater Boston area, a major hub for biotechnology and life sciences companies. While the company develops therapies for autoimmune diseases that affect patients globally, its current clinical trial for JADE101 and preclinical programs are conducted in the U.S. The company does not have disclosed operations or partnerships outside the United States.
Does Jade Biosciences (JBIO) have any notable partnerships or collaborations?
Yes, Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. This partnership likely supports the development of Jade Biosciences' pipeline, including JADE101, JADE201, and JADE-003. Paragon Therapeutics is a biotechnology company that specializes in antibody discovery and development, so the collaboration may involve research and development services or licensing of technology. The specific terms of the agreement are not detailed in the available data, but such collaborations are common in the biotech industry to share expertise and reduce development costs. Jade Biosciences is based in Waltham, Massachusetts, and continues to advance its programs through this partnership.